Metabolomics analysis of patients with Schistosoma japonicum infection based on UPLC-MS method.
Humans
Schistosomiasis japonica
/ parasitology
Metabolomics
/ methods
Schistosoma japonicum
/ metabolism
Male
Female
Animals
Adult
Middle Aged
Mass Spectrometry
/ methods
Biomarkers
/ blood
Metabolome
Chromatography, High Pressure Liquid
/ methods
Aged
Young Adult
Chromatography, Liquid
/ methods
Liquid Chromatography-Mass Spectrometry
Schistosoma japonicum
Biomarker
Metabolomics
UPLC-MS
Journal
Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774
Informations de publication
Date de publication:
20 Aug 2024
20 Aug 2024
Historique:
received:
20
03
2024
accepted:
30
07
2024
medline:
21
8
2024
pubmed:
21
8
2024
entrez:
20
8
2024
Statut:
epublish
Résumé
Schistosomiasis is still one of the most serious parasitic diseases. Evidence showed that the metabolite profile in serum can potentially act as a marker for parasitic disease diagnosis and evaluate disease progression and prognosis. However, the serum metabolome in patients with Schistosoma japonicum infection is not well defined. In this study, we investigated the metabolite profiles of patients with chronic and with advanced S. japonicum infection. The sera of 33 chronic S. japonicum patients, 15 patients with advanced schistosomiasis and 17 healthy volunteers were collected. Samples were extracted for metabolites and analyzed with ultra-performance liquid chromatography-mass spectrometry (UPLC-MS). We observed significant differences in metabolite profiles in positive and negative ion modes between patients with advanced and chronic S. japonicum infection. In patients with chronic S. japonicum infection, 199 metabolites were significantly upregulated while 207 metabolites were downregulated in advanced infection. These differential metabolites were mainly concentrated in steroid hormone biosynthesis, cholesterol metabolism and bile secretion pathways. We also found that certain bile acid levels were significantly upregulated in the progression from chronic to advanced S. japonicum infection. In receiver operator characteristic (ROC) analysis, we identified three metabolites with area under the curve (AUC) > 0.8, including glycocholic (GCA), glycochenodeoxycholate (GCDCA) and taurochenodeoxycholic acid (TCDCA) concentrated in cholesterol metabolism, biliary secretion and primary bile acid biosynthesis. This study provides evidence that GCA, GCDCA and TCDCA can potentially act as novel metabolite biomarkers to distinguish patients in different stages of S. japonicum infection. This study will contribute to the understanding of the metabolite mechanisms of the transition from chronic to advanced S. japonicum infection, although more studies are needed to validate this potential role and explore the underlying mechanisms.
Sections du résumé
BACKGROUND
BACKGROUND
Schistosomiasis is still one of the most serious parasitic diseases. Evidence showed that the metabolite profile in serum can potentially act as a marker for parasitic disease diagnosis and evaluate disease progression and prognosis. However, the serum metabolome in patients with Schistosoma japonicum infection is not well defined. In this study, we investigated the metabolite profiles of patients with chronic and with advanced S. japonicum infection.
METHODS
METHODS
The sera of 33 chronic S. japonicum patients, 15 patients with advanced schistosomiasis and 17 healthy volunteers were collected. Samples were extracted for metabolites and analyzed with ultra-performance liquid chromatography-mass spectrometry (UPLC-MS).
RESULTS
RESULTS
We observed significant differences in metabolite profiles in positive and negative ion modes between patients with advanced and chronic S. japonicum infection. In patients with chronic S. japonicum infection, 199 metabolites were significantly upregulated while 207 metabolites were downregulated in advanced infection. These differential metabolites were mainly concentrated in steroid hormone biosynthesis, cholesterol metabolism and bile secretion pathways. We also found that certain bile acid levels were significantly upregulated in the progression from chronic to advanced S. japonicum infection. In receiver operator characteristic (ROC) analysis, we identified three metabolites with area under the curve (AUC) > 0.8, including glycocholic (GCA), glycochenodeoxycholate (GCDCA) and taurochenodeoxycholic acid (TCDCA) concentrated in cholesterol metabolism, biliary secretion and primary bile acid biosynthesis.
CONCLUSIONS
CONCLUSIONS
This study provides evidence that GCA, GCDCA and TCDCA can potentially act as novel metabolite biomarkers to distinguish patients in different stages of S. japonicum infection. This study will contribute to the understanding of the metabolite mechanisms of the transition from chronic to advanced S. japonicum infection, although more studies are needed to validate this potential role and explore the underlying mechanisms.
Identifiants
pubmed: 39164750
doi: 10.1186/s13071-024-06429-9
pii: 10.1186/s13071-024-06429-9
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
350Subventions
Organisme : National Natural Science Foundation of China
ID : 81901630
Organisme : National Natural Science Foundation of China
ID : 81771722
Organisme : Natural Science Foundation of Hunan Province of China
ID : 2021JJ40959
Organisme : the Key research and Development Plan of Hunan Province
ID : 2021SK2032
Informations de copyright
© 2024. The Author(s).
Références
Utzinger J, Becker SL, Knopp S, Blum J, Neumayr AL, Keiser J. Hatz CF Neglected tropical diseases: diagnosis, clinical management, treatment and control. Swiss Med Week. 2012;142:w13727.
Adenowo AF, Oyinloye BE, Ogunyinka BI, Kappo AP. Impact of human schistosomiasis in sub-Saharan Africa. Braz J Infect Dis. 2015;19:196–205.
pubmed: 25636189
pmcid: 9425372
doi: 10.1016/j.bjid.2014.11.004
Gray DJ, McManus DP, Li Y, Williams GM, Bergquist R, Ross AG. Schistosomiasis elimination: lessons from the past guide the future. Lancet Infect Dis. 2010;10:733–6.
pubmed: 20705513
doi: 10.1016/S1473-3099(10)70099-2
Schistosomiasis: number of people receiving preventive chemotherapy in 2012. Releve epidemiologique hebdomadaire. 2014;89:21–8.
Freer JB, Bourke CD, Durhuus GH, Kjetland EF, Prendergast AJ. Schistosomiasis in the first 1000 days. Lancet Infect Dis. 2018;18:e193–203.
pubmed: 29170089
doi: 10.1016/S1473-3099(17)30490-5
Huang Y, Lu J, Xu Y, Xiong C, Tong D, Hu N, et al. Xiaochaihu decorction relieves liver fibrosis caused by Schistosoma japonicum infection via the HSP47/TGF-β pathway. Parasit Vectors. 2020;13:254.
pubmed: 32410640
pmcid: 7227055
doi: 10.1186/s13071-020-04121-2
Von Lichtenberg F, Erickson DG, Sadun EH. Comparative histopathology of Schistosome granulomas in the hamster. Am J Pathol. 1973;72:149–78.
Zheng L, Wang L, Hu Y, Yi J, Wan L, Shen Y, et al. Higher frequency of circulating Vδ1 γδT cells in patients with advanced Schistosomiasis. Parasite Immunol. 2021;43:e12871.
pubmed: 34037255
pmcid: 9285544
doi: 10.1111/pim.12871
MacGregor SR, McManus DP, Sivakumaran H, Egwang TG, Adriko M, Cai P, et al. Development of CRISPR/Cas13a-based assays for the diagnosis of Schistosomiasis. EBioMedicine. 2023;94:104730.
pubmed: 37487416
pmcid: 10382885
doi: 10.1016/j.ebiom.2023.104730
Amoah AS, Hoekstra PT, Casacuberta-Partal M, Coffeng LE, Corstjens PL, Greco B, et al. Sensitive diagnostic tools and targeted drug administration strategies are needed to eliminate schistosomiasis. Lancet Infect Dis. 2020;20:e165–72.
pubmed: 32595046
doi: 10.1016/S1473-3099(20)30254-1
He P, Gordon CA, Williams GM, Li Y, Wang Y, Hu J, et al. Real-time PCR diagnosis of Schistosoma japonicum in low transmission areas of China. Infect Dis Poverty. 2018;7:8.
pubmed: 29394958
pmcid: 5796516
doi: 10.1186/s40249-018-0390-y
Weerakoon KG, McManus DP. Cell-free DNA as a diagnostic tool for human parasitic infections. Trends Parasitol. 2016;32:378–91.
pubmed: 26847654
doi: 10.1016/j.pt.2016.01.006
Huang Y, Xu Y, Huang Y, Sun F, Tian H, Hu N, et al. Identification of newly developed advanced schistosomiasis with MALDI-TOF mass spectrometry and ClinProTools analysis. Parasite. 2019;26:33.
pubmed: 31166908
pmcid: 6550559
doi: 10.1051/parasite/2019032
Huang Y, Wu Q, Zhao L, Xiong C, Xu Y, Dong X, et al. UHPLC-MS-based metabolomics analysis reveals the process of schistosomiasis in mice. Front Microbiol. 2020;11:1517.
pubmed: 32760365
pmcid: 7371968
doi: 10.3389/fmicb.2020.01517
Wu J, Xu W, Ming Z, Dong H, Tang H, Wang Y. Metabolic changes reveal the development of schistosomiasis in mice. PLoS Negl Trop Dis. 2010;4(8):e807.
pubmed: 20824219
pmcid: 2930859
doi: 10.1371/journal.pntd.0000807
Tounta V, Liu Y, Cheyne A, Larrouy-Maumus G. Metabolomics in infectious diseases and drug discovery. Mol Omics. 2021;17:376–93.
pubmed: 34125125
pmcid: 8202295
doi: 10.1039/D1MO00017A
Chinese Center for Disease Control and Prevention ea. Diagnostic Criteria for Schistosomiasis (WS261–2006). 2006.
Li Y, Mei L, Qiang J, Ju S, Zhao S. Magnetic resonance spectroscopy for evaluating portal-systemic encephalopathy in patients with chronic hepatic Schistosomiasis Japonicum. PLoS Negl Trop Dis. 2016;10:e0005232.
pubmed: 27977668
pmcid: 5199111
doi: 10.1371/journal.pntd.0005232
Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc. 2011;6:1060–83.
pubmed: 21720319
doi: 10.1038/nprot.2011.335
Di Guida R, Engel J, Allwood JW, Weber RJ, Jones MR, Sommer U, et al. Non-targeted UHPLC-MS metabolomic data processing methods: a comparative investigation of normalisation, missing value imputation, transformation and scaling. Metabolomics. 2016;12:93.
pubmed: 27123000
pmcid: 4831991
doi: 10.1007/s11306-016-1030-9
Hakimi AA, Reznik ED, Lee CH, Creighton CJ, Brannon AR, Luna A, et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell. 2016;29:104–16.
pubmed: 26766592
pmcid: 4809063
doi: 10.1016/j.ccell.2015.12.004
Li R, Yang L, Guan S, Lin M, Lai H, Liu K, et al. UPLC-MS-based serum metabolic profiling reveals potential biomarkers for predicting propofol responsiveness in females. J Proteome Res. 2021;20:4578–88.
pubmed: 34384217
doi: 10.1021/acs.jproteome.1c00554
Venkatesan P. Defeating meningitis by 2030: the WHO roadmap. Lancet Infect Dis. 2021;21:1635.
pubmed: 34838228
doi: 10.1016/S1473-3099(21)00712-X
Kur P, Kolasa-Wołosiuk A, Misiakiewicz-Has K, Wiszniewska B. Sex hormone-dependent physiology and diseases of liver. Int J Environ Res Public Health. 2020;17(8):2620.
pubmed: 32290381
pmcid: 7216036
doi: 10.3390/ijerph17082620
Yang X, Ding W, Qian X, Jiang P, Chen Q, Zhang X, et al. Schistosoma japonicum infection leads to the reprogramming of glucose and lipid metabolism in the colon of mice. Front Vet Sci. 2021;8:645807.
pubmed: 33791356
pmcid: 8006365
doi: 10.3389/fvets.2021.645807
Liu Y, Zhang PP, Li JH, Li H, Zhou C, Zhang Y, et al. Correction: Association between serum lipid profile and liver fibrosis in patients infected with Schistosoma japonicum. Parasit Vectors. 2022;15:330.
pubmed: 36123750
pmcid: 9487035
doi: 10.1186/s13071-022-05470-w
Yang H, Li H, Chen W, Mei Z, Yuan Y, Wang X, et al. Therapeutic effect of Schistosoma japonicum cystatin on atherosclerotic renal damage. Front Cell Dev Biol. 2021;9:760980.
pubmed: 34901005
pmcid: 8656285
doi: 10.3389/fcell.2021.760980
Wu W, LoVerde PT. Nuclear hormone receptors in parasitic platyhelminths. Mol Biochem Parasitol. 2019;233:111218.
pubmed: 31470045
pmcid: 6783382
doi: 10.1016/j.molbiopara.2019.111218
Caussy C, Ajmera VH, Puri P, Hsu CL-S, Bassirian S, Mgdsyan M, et al. Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease. Gut. 2019;68:1884–92.
pubmed: 30567742
doi: 10.1136/gutjnl-2018-317584
Charlton M, Angulo P, Chalasani N, Merriman R, Viker K, Charatcharoenwitthaya P, et al. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology. 2008;47:484–92.
pubmed: 18220286
doi: 10.1002/hep.22063
Abd-Ella EM, El-Kott AF, El-Kenawy AE, Khalifa HS, Bin-Meferij MM, Alramlawy AM. Dehydroepiandrosterone protects against acetaminophen-induced liver damage in rats by upregulation of Bcl-2 and activation of sirt signalling. J Physiol Pharmacol. 2020;71(6):781–92.
Goicoechea L, de la Conde Rosa L, Torres S, García-Ruiz C, Fernández-Checa JC. Mitochondrial cholesterol: metabolism and impact on redox biology and disease. Redox Biol. 2023;61:102643.
pubmed: 36857930
pmcid: 9989693
doi: 10.1016/j.redox.2023.102643
Mizuochi T, Takei H, Nittono H, Kimura A. Inborn errors of bile acid metabolism in Japan. Pediatr int. 2023;65:e15490.
pubmed: 36704863
doi: 10.1111/ped.15490
Zhang B, Li J, Zong X, Wang J, Xin L, Song H, et al. FXR deficiency in hepatocytes disrupts the bile acid homeostasis and inhibits autophagy to promote liver injury in Schistosoma japonicum-infected mice. PLoS Negl Trop Dis. 2022;16:e0010651.
pubmed: 35930537
pmcid: 9355238
doi: 10.1371/journal.pntd.0010651
Greenberg RM. Schistosome ABC multidrug transporters: from pharmacology to physiology. Int J Parasitol Drugs Drug Resist. 2014;4:301–9.
pubmed: 25516841
pmcid: 4266782
doi: 10.1016/j.ijpddr.2014.09.007
Li JV, Holmes E, Saric J, Keiser J, Dirnhofer S, Utzinger J, et al. Metabolic profiling of a Schistosoma mansoni infection in mouse tissues using magic angle spinning-nuclear magnetic resonance spectroscopy. Int J Parasitol. 2009;39:547–58.
pubmed: 19068218
doi: 10.1016/j.ijpara.2008.10.010
Watanabe A, Hayashi S, Higashi T, Obata T, Sakata T, Takei N, et al. Characteristics change in serum amino acid levels in different types of hepatic encephalopathy. Gastroenterol Jpn. 1982;17:218–23.
pubmed: 7117780
doi: 10.1007/BF02775999
An Z, Hu T, Lv Y, Li P, Liu L. Targeted amino acid and related amines analysis based on iTRAQ -LCMS/ MS for discovering potential hepatotoxicity biomarkers. J Pharm Biomed Anal. 2020;178:112812.
pubmed: 31639596
doi: 10.1016/j.jpba.2019.112812
Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer. 2013;13:572–83.
pubmed: 23822983
pmcid: 3806315
doi: 10.1038/nrc3557
Meiser J, Tumanov S, Maddocks O, Labuschagne CF, Athineos D, Van Den Broek N, et al. Serine one-carbon catabolism with formate overflow. Sci Adv. 2016;2:e1601273.
pubmed: 27819051
pmcid: 5091358
doi: 10.1126/sciadv.1601273
Li Z, Wang F, Liang B, Su Y, Sun S, Xia S, et al. Methionine metabolism in chronic liver diseases: an update on molecular mechanism and therapeutic implication. Signal Transd Targeted Ther. 2020;5:280.
doi: 10.1038/s41392-020-00349-7
del Maria Bas J, Rodríguez B, Puiggròs F, Mariné S, Rodríguez MA, Morina D, et al. Hepatic accumulation of S-adenosylmethionine in hamsters with non-alcoholic fatty liver disease associated with metabolic syndrome under selenium and vitamin E deficiency. Clin Sci. 2019;133:409–23.
doi: 10.1042/CS20171039
Perez MJ, Briz O. Bile-acid-induced cell injury and protection. World J Gastroenterol. 2009;15:1677–89.
pubmed: 19360911
pmcid: 2668773
doi: 10.3748/wjg.15.1677
Lai J, Luo L, Zhou T, Feng X, Ye J, Zhong B. Alterations in circulating bile acids in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. Biomolecules. 2023;13(9):1356.
pubmed: 37759756
pmcid: 10526305
doi: 10.3390/biom13091356
Islam KS, Fukiya S, Hagio M, Fujii N, Ishizuka S, Ooka T, et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology. 2011;141:1773–81.
pubmed: 21839040
doi: 10.1053/j.gastro.2011.07.046
Vlahcevic ZR, Buhac I, Bell CC Jr, Swell L. Abnormal metabolism of secondary bile acids in patients with cirrhosis. Gut. 1970;11:420–2.
pubmed: 5428044
pmcid: 1411544
doi: 10.1136/gut.11.5.420
Yin P, Wan D, Zhao C, Chen J, Zhao X, Wang W, et al. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol Biosyst. 2009;5:868–76.
pubmed: 19603122
doi: 10.1039/b820224a
Wang X, Wang X, Xie G, Zhou M, Yu H, Lin Y, et al. Urinary metabolite variation is associated with pathological progression of the post-hepatitis B cirrhosis patients. J Proteome Res. 2012;11:3838–47.
pubmed: 22624806
doi: 10.1021/pr300337s
Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics: MCP. 2011;10:M110004945.
doi: 10.1074/mcp.M110.004945
Wang X, Xie G, Zhao A, Zheng X, Huang F, Wang Y, et al. Serum bile acids are associated with pathological progression of hepatitis B-induced cirrhosis. J Proteome Res. 2016;15:1126–34.
pubmed: 25964117
pmcid: 5660916
doi: 10.1021/acs.jproteome.5b00217
Sydor S, Best J, Messerschmidt I, Manka P, Vilchez-Vargas R, Brodesser S, et al. Altered microbiota diversity and bile acid signaling in cirrhotic and noncirrhotic NASH-HCC. Clin Transl Gastroenterol. 2020;11:e00131.
pubmed: 32352707
pmcid: 7145043
doi: 10.14309/ctg.0000000000000131